Kitov Pharma Ltd. (“Kitov”; NASDAQ/TASE: KTOV) is a clinical-stage company focusing on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, to create successful ...

Company to Evaluate NT219 as Monotherapy Treatment of Advanced Solid Tumors and in Combination with Cetuximab for Treatment of Recurrent or Metastatic Solid Tumors and Head and Neck Cancer in a Phase ...

Kitov Pharmaceuticals has bought a 56% stake in TyrNovo to take control of a cancer program. The focal point of the deal is NT219, an IRS-1/2-targeting drug designed to improve the efficacy of other ...

TEL AVIV, Israel, Sept. 09, 2019 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and ...

Shares of Kitov Pharma KTOV skyrocketed about 169% as the company’s anti-cancer candidate, NT219 yielded encouraging results. The company announced new findings from its NT219 treatment to battle ...

Israel’s Kitov Pharmaceuticals Holdings is taking a majority equity stake in cancer immunotherapeutics firm TyrNovo to expand its own noncancer pipeline with TyrNovo’s preclinical-stage small-molecule ...

TEL AVIV, Israel, Dec. 15, 2015 /PRNewswire/ -- Kitov Pharmaceuticals (NASDAQ/TASE: KTOV), an innovative biopharmaceutical company focused on late-stage drug development, announced today that the ...

Company Expects to Initiate Phase 1/2 Trial of NT-219 as Monotherapy Treatment of Advanced Solid Tumors and in Combination with cetuximab for Treatment of Recurrent or Metastatic Solid Tumors and Head ...

TEL-AVIV, Israel, April 20, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and ...

Kitov’s Chairman and CMO Dr. Paul Waymack subpoenaed by SEC. Review of first half of 2018 corporate update. Kitov wants a United States Commercial Partner for their osteoarthritic pain and ...